| UniProt ID | SUMO2_HUMAN | |
|---|---|---|
| UniProt AC | P61956 | |
| Protein Name | Small ubiquitin-related modifier 2 {ECO:0000305} | |
| Gene Name | SUMO2 {ECO:0000312|HGNC:HGNC:11125} | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 95 | |
| Subcellular Localization | Nucleus. Nucleus, PML body. | |
| Protein Description | Ubiquitin-like protein that can be covalently attached to proteins as a monomer or as a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2, CBX4 or ZNF451. [PubMed: 26524494 This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Polymeric SUMO2 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins] | |
| Protein Sequence | MADEKPKEGVKTENNDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGGVY | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 5 | Sumoylation | ---MADEKPKEGVKT ---CCCCCCCCCCCC | 63.03 | - | |
| 5 | Ubiquitination | ---MADEKPKEGVKT ---CCCCCCCCCCCC | 63.03 | 21890473 | |
| 5 | Acetylation | ---MADEKPKEGVKT ---CCCCCCCCCCCC | 63.03 | 3755499 | |
| 5 | Sumoylation | ---MADEKPKEGVKT ---CCCCCCCCCCCC | 63.03 | 28112733 | |
| 7 | Sumoylation | -MADEKPKEGVKTEN -CCCCCCCCCCCCCC | 77.49 | - | |
| 7 | Ubiquitination | -MADEKPKEGVKTEN -CCCCCCCCCCCCCC | 77.49 | 21890473 | |
| 7 | Acetylation | -MADEKPKEGVKTEN -CCCCCCCCCCCCCC | 77.49 | 21339330 | |
| 7 | Sumoylation | -MADEKPKEGVKTEN -CCCCCCCCCCCCCC | 77.49 | 28112733 | |
| 11 | Acetylation | EKPKEGVKTENNDHI CCCCCCCCCCCCCCE | 62.06 | 19608861 | |
| 11 | Sumoylation | EKPKEGVKTENNDHI CCCCCCCCCCCCCCE | 62.06 | - | |
| 11 | Ubiquitination | EKPKEGVKTENNDHI CCCCCCCCCCCCCCE | 62.06 | 21906983 | |
| 11 | Sumoylation | EKPKEGVKTENNDHI CCCCCCCCCCCCCCE | 62.06 | 19608861 | |
| 12 | Phosphorylation | KPKEGVKTENNDHIN CCCCCCCCCCCCCEE | 41.35 | 25159151 | |
| 21 | Acetylation | NNDHINLKVAGQDGS CCCCEEEEECCCCCC | 26.08 | 25953088 | |
| 21 | Ubiquitination | NNDHINLKVAGQDGS CCCCEEEEECCCCCC | 26.08 | 21890473 | |
| 21 | Sumoylation | NNDHINLKVAGQDGS CCCCEEEEECCCCCC | 26.08 | 28112733 | |
| 21 | Sumoylation | NNDHINLKVAGQDGS CCCCEEEEECCCCCC | 26.08 | - | |
| 21 | Ubiquitination | NNDHINLKVAGQDGS CCCCEEEEECCCCCC | 26.08 | 21906983 | |
| 28 | Phosphorylation | KVAGQDGSVVQFKIK EECCCCCCEEEEEEE | 27.66 | 30266825 | |
| 33 | Sumoylation | DGSVVQFKIKRHTPL CCCEEEEEEEECCHH | 30.17 | - | |
| 33 | Ubiquitination | DGSVVQFKIKRHTPL CCCEEEEEEEECCHH | 30.17 | 21890473 | |
| 33 | Methylation | DGSVVQFKIKRHTPL CCCEEEEEEEECCHH | 30.17 | 72586761 | |
| 33 | Acetylation | DGSVVQFKIKRHTPL CCCEEEEEEEECCHH | 30.17 | 72586761 | |
| 33 | Sumoylation | DGSVVQFKIKRHTPL CCCEEEEEEEECCHH | 30.17 | - | |
| 33 | Ubiquitination | DGSVVQFKIKRHTPL CCCEEEEEEEECCHH | 30.17 | 21890473 | |
| 35 | Ubiquitination | SVVQFKIKRHTPLSK CEEEEEEEECCHHHH | 38.42 | 21890473 | |
| 35 | Sumoylation | SVVQFKIKRHTPLSK CEEEEEEEECCHHHH | 38.42 | - | |
| 35 | Ubiquitination | SVVQFKIKRHTPLSK CEEEEEEEECCHHHH | 38.42 | 21890473 | |
| 38 | Phosphorylation | QFKIKRHTPLSKLMK EEEEEECCHHHHHHH | 29.92 | 28152594 | |
| 41 | Phosphorylation | IKRHTPLSKLMKAYC EEECCHHHHHHHHHH | 25.58 | 28152594 | |
| 42 | Sumoylation | KRHTPLSKLMKAYCE EECCHHHHHHHHHHH | 61.35 | 19608861 | |
| 42 | Ubiquitination | KRHTPLSKLMKAYCE EECCHHHHHHHHHHH | 61.35 | 21890473 | |
| 42 | Sumoylation | KRHTPLSKLMKAYCE EECCHHHHHHHHHHH | 61.35 | - | |
| 42 | Acetylation | KRHTPLSKLMKAYCE EECCHHHHHHHHHHH | 61.35 | 19608861 | |
| 42 | Ubiquitination | KRHTPLSKLMKAYCE EECCHHHHHHHHHHH | 61.35 | 21890473 | |
| 45 | Sumoylation | TPLSKLMKAYCERQG CHHHHHHHHHHHHCC | 46.79 | - | |
| 45 | Acetylation | TPLSKLMKAYCERQG CHHHHHHHHHHHHCC | 46.79 | 19608861 | |
| 45 | Methylation | TPLSKLMKAYCERQG CHHHHHHHHHHHHCC | 46.79 | 19608861 | |
| 45 | Ubiquitination | TPLSKLMKAYCERQG CHHHHHHHHHHHHCC | 46.79 | 21906983 | |
| 45 | Sumoylation | TPLSKLMKAYCERQG CHHHHHHHHHHHHCC | 46.79 | 19608861 | |
| 45 | Ubiquitination | TPLSKLMKAYCERQG CHHHHHHHHHHHHCC | 46.79 | 21890473 | |
| 50 | Methylation | LMKAYCERQGLSMRQ HHHHHHHHCCCCCEE | 32.10 | - | |
| 54 | Phosphorylation | YCERQGLSMRQIRFR HHHHCCCCCEEEEEE | 20.81 | 30377224 | |
| 83 | Phosphorylation | LEMEDEDTIDVFQQQ ECCCCCCCEEHHHHH | 19.61 | 24732914 | |
| 91 | Phosphorylation | IDVFQQQTGGVY--- EEHHHHHCCCCC--- | 31.40 | 24732914 | |
| 95 | Phosphorylation | QQQTGGVY------- HHHCCCCC------- | 18.99 | 24043423 |
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of SUMO2_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Acetylation | |
| Reference | PubMed |
| "Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-11, AND MASS SPECTROMETRY. | |
| Sumoylation | |
| Reference | PubMed |
| "In vivo identification of sumoylation sites by a signature tag andcysteine-targeted affinity purification."; Blomster H.A., Imanishi S.Y., Siimes J., Kastu J., Morrice N.A.,Eriksson J.E., Sistonen L.; J. Biol. Chem. 285:19324-19329(2010). Cited for: SUMOYLATION AT LYS-11. | |
| "RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required forarsenic-induced PML degradation."; Tatham M.H., Geoffroy M.C., Shen L., Plechanovova A., Hattersley N.,Jaffray E.G., Palvimo J.J., Hay R.T.; Nat. Cell Biol. 10:538-546(2008). Cited for: FUNCTION, AND POLYUBIQUITINATION AT LYS-11 BY RNF4. | |
| "Polymeric chains of SUMO-2 and SUMO-3 are conjugated to proteinsubstrates by SAE1/SAE2 and Ubc9."; Tatham M.H., Jaffray E., Vaughan O.A., Desterro J.M.P., Botting C.H.,Naismith J.H., Hay R.T.; J. Biol. Chem. 276:35368-35374(2001). Cited for: SUMOYLATION AT LYS-11, AND MUTAGENESIS OF LYS-11. | |